Last reviewed · How we verify

Yu-Ching HSU — Portfolio Competitive Intelligence Brief

Yu-Ching HSU pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Xiao-Yao-San Xiao-Yao-San marketed Mental Health / Digestive Health (Traditional Chinese Medicine)

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Yu-Ching HSU:

Cite this brief

Drug Landscape (2026). Yu-Ching HSU — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yu-ching-hsu. Accessed 2026-06-10.

Related